What does “research use only” mean for peptides?

What does “research use only” mean on a peptide?

It means the seller says the product is for laboratory research, not for human or veterinary use. Products sold this way are not approved drugs and are not made to drug standards, so their identity, purity, sterility and strength are unverified. FDA warning letter

The label does not decide what FDA treats a product as. In an August 2026 warning letter, FDA said that despite labeling reading “for research use only” and “not for human or veterinary use,” evidence from the seller’s website established the products were intended to be drugs for human use. FDA warning letter

Why are research-only peptides not for people?

Because nobody has shown they are safe and effective in people, and nothing sold as a research chemical is made under drug manufacturing rules. For BPC-157, for example, FDA’s 2026 review found no studies giving it to humans by the routes it is marketed for. FDA briefing, BPC-157

FDA warning letters also note that injectable products bypass some of the body’s natural defenses, which raises the stakes of contamination. FDA warning letter

What are FDA’s Category 1 and Category 2 bulk drug substances?

They are FDA’s interim lists for ingredients nominated for pharmacy compounding under section 503A. Category 1 substances are under evaluation and may be compounded under FDA’s interim policy. Category 2 substances may present significant safety risks, and under FDA’s interim policy pharmacies should not compound them. FDA

Category 1 is the list of bulk substances FDA is still evaluating that pharmacies may compound under interim conditions. NAD and enclomiphene citrate are examples. Being on it is not an FDA approval. FDA

Category 2 is the list of bulk substances that may present significant safety risks. As of its April 2026 update it names peptides including GHRP-2, GHRP-6, ipamorelin and kisspeptin-10. FDA

On April 15, 2026, FDA removed 12 peptides from Category 2, including BPC-157 and TB-500, and scheduled advisory committee meetings to review them. Orrick

What happened at FDA’s July 2026 advisory committee on peptides?

On July 23 and 24, 2026, FDA’s Pharmacy Compounding Advisory Committee voted on whether several peptides should be added to the 503A bulks list. It backed most of them, often narrowly and against FDA staff advice. The votes are advice only: FDA must still decide and complete rulemaking. McDermott Will & Schulte

FDA’s briefing documents set out the use reviewed for each peptide: wound healing for TB-500, for example. FDA briefing, TB-500

For DSIP, FDA focused its review on chronic insomnia, and the committee voted against adding it. FDA briefing, emideltide (DSIP)

Which peptides on DiscoverMedica are research only?

Every compound below is listed as research only: not approved for human use in the US and with no settled lawful compounding route. Each page explains its status, the evidence and the risks. DiscoverMedica links to no seller of any of them.

• RetatrutideAn investigational triple-hormone weight-loss drug from Eli Lilly. Not approved; only available in trials.
• BPC-157A lab-made peptide popular for injury recovery. Mostly animal data, and not an approved drug.
• TB-500A synthetic fragment of thymosin beta-4 marketed for recovery. Animal data only; not approved.
• EpitalonA four-amino-acid peptide marketed for aging and sleep. Limited research, not an approved drug.
• MOTS-cA peptide encoded by mitochondria, studied in mice for metabolism. Human data are minimal.
• DSIPA 1970s "sleep peptide" sold online. Human results were inconsistent and it is not approved.
• SemaxA Russian nasal peptide marketed for focus. Approved in Russia, not in the US.
• SelankA Russian peptide marketed for anxiety and focus. Not approved or compoundable in the US.
• Kisspeptin-10A reproductive-hormone peptide studied in fertility research. Restricted from compounding.
• IpamorelinA growth-hormone-releasing peptide sold online for body composition. Not approved.
• CJC-1295A long-acting growth-hormone-releasing peptide sold online, often with ipamorelin. Not approved.
• CagrilintideAn investigational long-acting amylin analog being studied alone and with semaglutide.
• SurvodutideAn investigational glucagon and GLP-1 receptor agonist studied for obesity and liver disease.
• MazdutideA glucagon and GLP-1 receptor agonist approved in China but not approved in the US.
• EloralintideAn investigational amylin-receptor agonist being studied by Eli Lilly for obesity.
• AOD-9604A modified growth-hormone fragment promoted for fat loss without an FDA-approved use.
• Melanotan IIAn unapproved pigment-stimulating peptide sold online for tanning and sexual effects.
• Thymosin alpha-1An immune-signaling peptide approved in some countries but not FDA-approved in the US.
• TesofensineAn investigational small-molecule weight-loss drug often grouped into RUO peptide catalogs.
• CerebrolysinAn injectable peptide mixture used in some countries but not FDA-approved in the US.
• IGF-1 LR3A long-acting laboratory analog of IGF-1 with no FDA-approved human use.

How can you tell a research peptide from a prescription drug?

A lawful prescription peptide comes from a licensed pharmacy on a prescription from a licensed clinician, and an FDA-approved one has official prescribing information you can look up on DailyMed. A research peptide is sold without a prescription, carries a “not for human consumption” style label, and has no approved labeling. Wegovy label

• No prescription or clinician involved: a warning sign for anything meant to be injected or swallowed.
• Labels such as “research use only” or “not for human use” next to health claims: the combination FDA cites in warning letters. FDA warning letter
• No DailyMed prescribing information and no named licensed pharmacy: there is no approved or compounded product behind it.

What “research use only” means: questions, answered

Sources

1. FDA warning letter: Peptide Partners (Aug 24, 2026)
2. FDA warning letter: Gram Peptides (Mar 31, 2026)
3. FDA warning letter: Summit Research Peptides (Dec 10, 2024)
4. FDA briefing document for the July 2026 advisory committee: BPC-157
5. FDA briefing document for the July 2026 advisory committee: TB-500
6. FDA briefing document for the July 2026 advisory committee: emideltide (DSIP)
7. FDA: 503A bulk drug substance categories list (May 14, 2026)
8. FDA: Bulk drug substances that may present significant safety risks (Category 2)
9. Orrick: FDA removes 12 peptides from Category 2 and schedules PCAC meetings (Apr 2026)
10. FDA: Pharmacy Compounding Advisory Committee, July 23-24, 2026
11. McDermott Will & Schulte: PCAC backs majority of peptides in two-day public meeting (July 2026)
12. DailyMed: Wegovy (semaglutide) prescribing information, revised June 2026

Last reviewed September 23, 2026. Every source above was checked on or before that date. Educational information only, not medical advice; it does not replace a conversation with a licensed clinician. DiscoverMedica does not employ clinicians.